Please assess the completion status of the following clinical trial:

Trial Title: MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~For Safety Run-in and Part 2 or Phase 2 Randomised Part~* Histologically confirmed K-Ras mutated colon/rectum cancer~* Subject's disease must have progressed during or after a first-line treatment for metastatic disease with oxaliplatin and fluoropyrimidines based chemotherapy with or without bevacizumab~* Evidence of metastatic measurable disease at trial entry as per Response Evaluation Criteria in Solid Tumors. Complete tumor assessment performed within 14 days prior to first trial drug administration~* Male/female subjects aged greater than or equal to (\>=) 18 years~* Subject has read and understood the informed consent form~* Women of childbearing potential must have a negative blood pregnancy test at the screening visit. Subjects and their partners must be willing to avoid pregnancy during the trial~Exclusion Criteria:~For Safety Run-in and Part 2 or Phase 2 Randomised Part~* Bone marrow impairment~* Renal impairment~* Liver function and liver cell integrity abnormality~* History of central nervous system (CNS) metastases~* History of difficulty of swallowing, malabsorption or other chronic gastrointestinal disease~* Eastern Cooperative Oncology Group Performance Status (ECOG PS) greater than (\>)1~* Known human immunodeficiency virus (HIV) positivity, active hepatitis C, or active hepatitis B~* Has received extensive prior radiotherapy on more than 30 percent (%) of bone marrow reserves, or prior bone marrow/stem cell transplantation~* Has received chemotherapy, any investigational drug, or having participated in another clinical trial within the past 4 weeks prior to trial first drug administration~* Has a history of any other significant medical disease~* Past or current history (within the last 2 years prior to inclusion) of malignancies except for the indication under this study~* Has significant cardiac conduction abnormalities and/or pacemaker~* Is a pregnant or nursing female~* Has retinal degenerative disease, history of uveitis, or history of retinal vein occlusion~* Other significant disease that in the Investigator's opinion would exclude the subject from the trial~* Known hypersensitivity to the trial treatment(s) or diluents (when applicable), including placebo or other comparator drug(s)~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI (Type: EXPERIMENTAL): None
- Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI (Type: EXPERIMENTAL): Planned, not performed
- Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI (Type: EXPERIMENTAL): Planned, not performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy